Discussion
A Parkinson’s disease therapy delivered through a wearable device eased motor function in some patients with advanced Parkinson’s, according to preliminary observations from an ongoing Phase 1b trial. An independent safety monitoring committee recommended that the trial of SER-252, Serina Therapeutics’ long-acting form of apomorphine, advance to a…
